R
Robert L. Martuza
Researcher at Harvard University
Publications - 264
Citations - 30135
Robert L. Martuza is an academic researcher from Harvard University. The author has contributed to research in topics: Oncolytic virus & Herpes simplex virus. The author has an hindex of 79, co-authored 263 publications receiving 27228 citations. Previous affiliations of Robert L. Martuza include Georgetown University Medical Center & House Ear Institute.
Papers
More filters
Journal ArticleDOI
Cingulotomy for refractory obsessive-compulsive disorder. A long-term follow-up of 33 patients.
Michael A. Jenike,Lee Baer,H. Thomas Ballantine,Robert L. Martuza,Susan Tynes,Ida Giriunas,M. Lynn Buttolph,Ned H. Cassem +7 more
TL;DR: The results of this investigation support the use of cingulotomy as a potentially effective treatment for patients with severe and disabling obsessive-compulsive disorder.
Journal ArticleDOI
Gene therapy of malignant brain tumors: a rat glioma line bearing the herpes simplex virus type 1-thymidine kinase gene and wild type retrovirus kills other tumor cells.
Yoshiaki Takamiya,M. P. Short,Z. D. Ezzeddine,F. L. Moolten,F. L. Moolten,Xandra O. Breakefield,Robert L. Martuza +6 more
TL;DR: The observations show that tumor cells modified in culture by infection with a Retrovirus bearing the HSV‐TK gene and wild type retrovirus are not only sensitive to ganciclovir, but can transfer this sensitivity to neighboring “naive” tumor cells in culture and in vivo.
Journal ArticleDOI
Attenuated, Replication-Competent Herpes Simplex Virus Type 1 Mutant G207: Safety Evaluation of Intracerebral Injection in Nonhuman Primates
William D. Hunter,Robert L. Martuza,Frank Feigenbaum,Tomoki Todo,Toshihiro Mineta,Takahito Yazaki,Masahiro Toda,Joseph T. Newsome,R. Craig Platenberg,Herbert J. Manz,Samuel D. Rabkin +10 more
TL;DR: It is concluded that intracerebral inoculation of up to 109 PFU of G207, well above the efficacious dose in mouse tumor studies, is safe and therefore appropriate for human clinical trials.
Journal Article
In Situ Cancer Vaccination: An IL-12 Defective Vector/Replication-Competent Herpes Simplex Virus Combination Induces Local and Systemic Antitumor Activity
TL;DR: It is concluded that this defective HSV vector system is an effective method for cytokine gene delivery to tumors in situ and IL-12 expression in tumors synergizes the antitumor activity mediated by the replication-competent HSV helper virus.
Journal ArticleDOI
Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model.
Tooba A. Cheema,Hiroaki Wakimoto,Peter E. Fecci,Jianfang Ning,Toshihiko Kuroda,Deva S. Jeyaretna,Robert L. Martuza,Samuel D. Rabkin +7 more
TL;DR: A murine glioblastoma stem cell (GSC) model is described that recapitulates tumor heterogeneity, invasiveness, vascularity, and immunosuppressive microenvironment in syngeneic immunocompetent mice and should prove useful for a range of therapeutic studies.